18:25 , Nov 9, 2018 |  BC Week In Review  |  Company News

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2...
13:33 , Nov 6, 2018 |  BC Extra  |  Company News

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2...
00:34 , Nov 3, 2018 |  BioCentury  |  Finance

Part B exposure

HHS Secretary Alex Azar's proposed changes to Medicare Part B have put at least four large biopharmas at risk of substantial U.S. revenue losses. But the lack of market reaction and the views of VCs...
18:13 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Keytruda, Inlyta combo headed for first-line RCC submissions

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab in combination with Inlyta axitinib met the primary endpoints vs. Sutent sunitinib in the Phase III KEYNOTE-426 trial as first-line treatment of renal cell carcinoma. Merck plans...
18:10 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

After three deals, FDA approval, talazoparib joins PARP party

FDA approved Talzenna talazoparib from Pfizer Inc. (NYSE:PFE) to treat germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, making it the second PARP inhibitor approved for the indication. The approval comes well ahead of...
18:00 , Oct 18, 2018 |  BC Extra  |  Clinical News

Keytruda, Inlyta combo headed for first-line RCC submissions

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab in combination with Inlyta axitinib met the primary endpoints vs. Sutent sunitinib in the Phase III KEYNOTE-426 trial as first-line treatment of renal cell carcinoma. Merck plans...
22:50 , Oct 16, 2018 |  BC Extra  |  Company News

After three deals, FDA approval talazoparib joins PARP party

FDA approved Talzenna talazoparib from Pfizer Inc. (NYSE:PFE) to treat germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, making it the second PARP inhibitor approved for the indication. The approval comes well ahead of...
20:00 , Oct 5, 2018 |  BC Week In Review  |  Company News

Immutep, Merck KGgA, Pfizer partner for Phase I immunotherapy combo trial

Immutep Ltd. (ASX:IMM; NASDAQ:IMMP), Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) partnered to test Immutep's eftilagimod alpha (IMP321) in combination with the pharmas' anti-PD-L1 mAb Bavencio avelumab in a Phase I trial for patients with...
19:55 , Sep 28, 2018 |  BC Week In Review  |  Company News

China Medical gets Asian rights to Vaximm's immunotherapy portfolio

China Medical System Holdings Ltd. (HKSE:867) gained an exclusive license from Vaximm AG (Basel, Switzerland) to develop and commercialize Vaximm's oral cancer immunotherapy pipeline in China, Hong Kong, Macau, Taiwan and other Asian countries. The...
21:32 , Sep 19, 2018 |  BC Innovations  |  Translation in Brief

To eat and not to eat

A...